Links:
Links:
Links:
Links:
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL
Read Article
Links:
A recent randomised clinical trial suggests immunomodulators reduce arterial inflammation, and thereby cardiovascular (CV) risk, but shows no significant benefit to TNF inhibitors over triple therapy in patients with rheumatoid arthritis (RA).
Read Article
The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
The exact role of diet, physical activity, and stress management in the management of RA has long been debated. While reasonable evidence has supported the importance of physical activity in patients with RA, its capacity to reduce disease activity via conventional measures such as DAS28 was
Read Article
Links:
Links:
While have come so far from the days of our patients living on massive doses of steroids, we still have many patients who use steroids for our diseases, with increasing data for toxicity, even in low dose. As someone much smarter than me described them, steroids are our best frenemy.
Read Article
Addressing chronic pain often leads general practitioners and specialists to prescribe opioids. However, opioids (weak and strong) have not demonstrated efficacy in long-term pain management; their chronic use could even worsen pain in users. Opioids prescription is often perceived as being
Read Article
Links:
Links:
Links:
Links:
